Mark Lebovitch Featured in Wall Street Journal Article Tracing Impact of 'Poison Puts' on Corporate Mergers - The Latest Effort To Undermine Shareholder Rights?
April 14, 2009
History has shown that corporate directors and senior executives often use creative devices to protect their own interests at the expense of shareholders. Dennis K. Berman, in his article for the The Wall Street Journal, explains that “Poison Puts” are just the latest device gaining popularity as a way to maintain control of the company and obstruct deals that may benefit shareholders.
“[T]he poison put is playing an unnoticed role in preventing a wave of deals. When a company takes out a loan or issues debt, the contract often requires that it pay back those debts in full when it buys a company or sells itself. That is the ‘put’ part -- because it protects bondholders. Sometimes companies must accelerate the payments when there is turnover in board or management. The idea is to protect lenders, ensuring that they are getting the kind of credit risk for which they originally bargained.”
However, because of Poison Puts, deals that can benefit shareholders may be undermined. For example, according to the article, Poison Puts may have complicated a pending sale of telecommunications firm Embarq Inc. to Century/Tel Inc. in November 2008 by making the acquisition unfeasible. As Mr. Lebovitch, quoted in the Journal, states, "For a levered-up company, it's a foolproof anti-activism device."
Activist investors, including some of the country's most prominent public pension funds, are fighting to protect shareholder interests. On March 24, 2009, BLB&G and its client the San Antonio Fire and Police Pension Fund filed a Complaint in Delaware state court against Amylin Pharmaceuticals, Inc. and its Board alleging violations of fiduciary duties by management and the Board arising from their adoption of defensive measures – including Poison Puts – in two debt instruments.
In 2007, amid takeover speculation, Amylin embedded Proxy Puts in its indenture agreement for $575 million of convertible notes and its $140 million credit agreement. The Proxy Puts expose the Company to immediate repayment and repurchase obligations if Amylin shareholders elect a board of directors that does not include a majority of the incumbent directors, or directors approved by the incumbent directors. These obligations could require Amylin to remit more than $900 million – an amount exceeding one-half of the Company’s current $1.7 billion market value. The Complaint seeks to invalidate the Proxy Puts, and require the Board to approve the nomination of a new slate of directors put forth by two other shareholders, Icahn Capital LP and Eastbourne Capital Management slates for shareholder consideration at the Company’s 2009 annual meeting. The Complaint also demands that Amylin correct coercive and misleading disclosures in its 2008 annual report.
Also of Interest
Lawdragon Profiles Mark Lebovitch in “Lawyer Limelight” Q&A
October 8, 2015
The National Law Journal Names Mark Lebovitch and Jeroen van Kwawegen 2018 Plaintiffs’ Lawyers Trailblazers
Law360 Once Again Names BLB&G Among the Nation’s “Most Feared Plaintiffs’ Firms”
September 28, 2015
Benchmark Names Mark Lebovitch One of the Nation’s Top 10 Securities Lawyers
Forbes Highlights Pivotal Role of Private Shareholder Litigation in Checking Corporate Misconduct
June 29, 2018
Mark Lebovitch Selected National “Plaintiff Attorney of the Year” by Benchmark
February 11, 2016
Mark Lebovitch Selected NYC “Lawyer of the Year” for M&A Litigation by The Best Lawyers in America©
August 17, 2015
Legal 500 Ranks BLB&G a National Tier 1 Firm for Securities and M&A Litigation
Law360 Names Mark Lebovitch a “Titan of the Plaintiffs Bar”
May 7, 2018
The National Law Journal Again Honors BLB&G as “Elite Trial Lawyers” Practice Area Award Winner
December 6, 2016